|
News
CritiTech Announces New Board Director
September 2, 2005
FOR IMMEDIATE RELEASE
Lawrence, Kan. - CritiTech today announced that Dr. Joseph
A. Fix has joined its Board of Directors. Dr. Fix has an extensive
drug delivery and pharmaceutical industry background in addition
to his experience in working in the micro and nanoparticle
pharmaceutical arena. Dr. Fix has over 25 years experience
in drug delivery, product development, operations, business
development, contract negotiations, and regulatory and quality
systems.
“We are very excited that Joe has
agreed to join CritiTech’s Board at this pivotal stage
in the company’s development. His broad base of experience
and expertise will be invaluable to the company as we progress
further into the commercialization stage in our business,”
said CEO and President Sam Campbell.
Dr. Fix has held a number of executive positions
in the pharmaceutical industry. Most recently he was President
and COO of Cydex, Inc. Previously he was EVP and COO of NanoSystems,
Inc., a unit of Elan Corporation. Before joining Elan, he
was President and CTO of Yamanouchi Pharma Technologies and
Associate Director of Biological Sciences for ALZA Corporation.
He began his career with Merck and Company, advancing to Associate
Director, Biopharmaceutics for the INTERx research division.
Dr. Fix holds a Ph.D. in neurophysiology
from the University of Kansas and an MBA from Pepperdine University.
He has held adjunct faculty positions at the University of
Southern California, Purdue University, and the University
of Kansas. He is the author of numerous publications and holds
17 patents in the drug delivery area.
CritiTech provides critical drug delivery
and development technology for the pharmaceutical industry.
CritiTech produces fine-particle pharmaceuticals including
nanoparticle pharmaceuticals using patented technologies developed
at the University of Kansas. The processes use compressed
carbon dioxide as the processing medium to produce relatively
residue-free and uniform drug microparticles and coatings.
The pharmaceutical industry has exhibited
substantial interest in processes that produce improved formulations
using nanoparticulate drugs in order to extend the patent
life of an existing drug or to enable the delivery of a poorly
soluble compound. CritiTech has also successfully used its
proprietary technology to coat medicinal agents either on
small particle drugs for improved drug delivery or as a thin
film on implantable medical devices such as cardiac stents.
The Nanotax™ ovarian cancer drug is the first drug to
be announced under the company’s drug development program.
|
